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Abstract
BACKGROUND & AIMS—Antiviral therapy could reduce the risk of hepatocellular carcinoma 
(HCC) among persons with chronic hepatitis B virus (HBV) infection. We evaluated the 
relationship between therapy for chronic HBV infection and HCC incidence using data from a 
longitudinal study of patients at 4 US healthcare centers.
METHODS—We analyzed electronic health records of 2671 adult participants in the Chronic 
Hepatitis Cohort Study who were diagnosed with chronic HBV infection from 1992 through 2011 
(49% Asian). Data analyzed were collected for a median of 5.2 years. Propensity-score adjustment 
was used to reduce bias, and Cox regression was used to estimate the relationship between 
antiviral treatment and HCC. The primary outcome was time to event of HCC incidence.
RESULTS—Of study subjects, 3% developed HCC during follow-up period: 20 cases among the 
820 patients with a history of antiviral HBV therapy and 47 cases among the 1851 untreated 
patients. In propensity-adjusted Cox regression, patients who received antiviral therapy had a 
lower risk of HCC than those who did not receive antiviral therapy (adjusted hazard ratio, 0.39; 
95% confidence interval, 0.27–0.56; P < .001), after adjusting for abnormal level of alanine 
aminotransferase. In a subgroup analysis, antiviral treatment was associated with a lower risk of 
HCC after adjusting for serum markers of cirrhosis (adjusted hazard ratio, 0.24; 95% confidence 
interval, 0.15–0.39; P < .001). In a separate subgroup analysis of patients with available data on 
Address requests for reprints to: Stuart C. Gordon, MD, Henry Ford Health System, 2799 West Grand Boulevard K-7, Detroit, 
Michigan 48202. sgordon3@hfhs.org. 
Conflicts of interest
This author discloses the following: Stuart C. Gordon receives grant and research support from AbbVie Pharmaceuticals, Bristol-
Myers Squibb, Gilead Pharmaceuticals, GlaxoSmithKline, Intercept Pharmaceuticals, Merck, and Vertex Pharmaceuticals. He is also a 
consultant for Amgen, Bristol-Myers Squibb, CVS Caremark, Gilead Pharmaceuticals, Merck, Novartis, and Vertex and is on the Data 
Monitoring Board for Janssen Pharmaceuticals. The remaining authors disclose no conflicts.
HHS Public Access
Author manuscript
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 December 07.
Published in final edited form as:
Clin Gastroenterol Hepatol. 2014 May ; 12(5): 885–893. doi:10.1016/j.cgh.2013.09.062.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
HBV DNA viral load, treated patients with viral loads >20,000 IU/mL had a significantly lower 
risk of HCC than untreated patients with viral loads >20,000 IU/mL.
CONCLUSIONS—In a large geographically, clinically, and racially diverse US cohort, antiviral 
therapy for chronic HBV infection was associated with a reduced risk for HCC.
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Recent comprehensive critical reviews,1 meta-analyses,2 and other studies3–5 have suggested 
that the use of various antiviral therapies for chronic hepatitis B virus (HBV) can reduce the 
risk of hepatocellular carcinoma (HCC) and HCC recurrence after liver resection.6 However, 
the definitive effect of antivirals on the development of HCC remains in doubt, because there 
is insufficient evidence from randomized controlled clinical trials to assess a treatment effect 
on clinical outcomes.7,8
Outstanding questions still remain. For example, it is unclear whether treatment of patients 
with noncirrhotic HBV eliminates the risk of HCC9; additionally, what benefits antiviral 
therapy has across a broad spectrum of viral load levels is uncertain. Observational studies 
and clinical trials examining the relationship between antiviral therapy and the development 
of HCC have generally been conducted in small cohorts that have been homogeneous in 
terms of geography, race, treatment, clinical profile, and/or viral characteristics. The Chronic 
Hepatitis Cohort Study (CHeCS) is a comprehensive, longitudinal cohort study assessing the 
clinical impact of chronic HBV and hepatitis C virus (HCV) infection in the United States.10 
Retrospective and real-time data are being collected at 4 large, integrated health systems 
serving approximately 4 million people in 5 geographically and racially disparate states, 
resulting in a diverse cohort. We examined whether antiviral HBV therapy was associated 
with a risk of HCC among CHeCS participants with chronic HBV infection.
Methods
CHeCS Cohort
The CHeCS investigation follows the guidelines of the US Department of Health and 
Human Services regarding the protection of human subjects. The protocol was approved and 
is renewed annually by the institutional review board at each participating site.
The CHeCS project’s methods have been summarized previously.10 Briefly, electronic 
administrative data and electronic health records of patients 18 years or older who had 
received any health services between January 1, 2006 and December 31, 2010 at a study site 
were used to identify candidates for the study cohort. For inclusion, patients had to fulfill at 
least 2 criteria (i.e., 2 positive laboratory tests consistent with current HBV infection 
[positive for HBV surface antigen, e-antigen, or DNA test], or a positive laboratory test and 
an International Classification of Diseases-9 diagnosis code, or 2 International Classification 
of Diseases-9 diagnosis codes obtained at least 6 months apart). Chronic HBV infection was 
then confirmed during chart abstraction. Eligibility for inclusion was not restricted to any 
particular chronic HBV disease phase.
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Time of HBV diagnosis was defined as the date of the earliest finding of an HBV-associated 
diagnosis code and/or a positive test for HBV infection within each health system’s records. 
Follow-up began with initiation of antiviral therapy in the treated group or time of HBV 
diagnosis in the untreated group, and ended with HCC, death, or last patient encounter.
Outcome
The primary outcome was time to event of HCC incidence. We searched for primary liver 
tumors in tumor registry records, which were implemented according to Surveillance, 
Epidemiology and End Results program standards at each site. Potential cancer cases for 
inclusion in the registry were based on a review of pathology and cytology reports, and 
credentialed cancer registrars completed data abstraction. Cancer diagnosis codes in 
administrative databases (International Classification of Diseases-9-CM codes in the range 
of 140–208.9) were also a source for registry case finding. Primary liver tumors diagnosed 
during the follow-up period were included as HCC cases. All confirmed HCC cases were 
incident cases, and 91% were established by anatomic pathology, cytology, and as reported 
on imaging reports in tumor registry records. The remaining were diagnosed clinically and 
by tumor marker.
To study the effect of antiviral HBV therapy on HCC incidence, antiviral treatment data 
were collected by chart abstraction, including any available documentation of treatment 
received at outside facilities. Patients were classified as having received antiviral HBV 
therapy if the patient had been treated with interferon α-2b, pegylated interferon α-2a or 
α-2b, lamivudine, entecavir, tenofovir, telbivudine, or adefovir and treatment had begun at 
least 1 year before HCC diagnosis (for patients who developed HCC) or the last encounter 
date (for patients not developing HCC). The 1-year interval was chosen to minimize both 
inclusion of preexisting malignancies in analyses of antiviral treatment effect and 
misattribution of treatment effect.
Control Variables
The methods for collecting demographic information were reported previously.10 Clinical 
data were collected from the electronic health records and included assessment of comorbid 
conditions, coinfection with human immunodeficiency virus (HIV), liver transplantation, 
and laboratory testing. We calculated the Charlson/Deyo comorbidity index score from 
diagnosis codes in inpatient, outpatient, and claims data during the year before chronic HBV 
infection was diagnosed.
Coinfection with HIV was determined by the presence of HIV antibodies or a detectable 
HIV RNA level on quantitative or qualitative testing and was included as time-dependent 
covariate in prediction of HCC development.
We collected data for alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
and platelet count during the 12 months before the diagnosis of chronic HBV infection. We 
then calculated 2 surrogate markers of liver fibrosis: the AST/platelet ratio index (APRI 
score); and a composite of 4 markers of fibrosis (FIB4), which is a composite of age, ALT, 
AST, and platelet count. If multiple values were available, the one closest to the time of 
HBV diagnosis was used. For analytical purposes, log transformation was used for APRI 
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and FIB4 because they were not normally distributed. ALT was categorized as normal or 
abnormal according to each site’s reference range, or as unknown.
We collected HBV DNA viral load data throughout the follow-up period. Viral loads were 
grouped into three categories (<2000, 2000–20,000, and >20,000 IU/mL) and were included 
as a time-dependent covariate in prediction of HCC development. Result values reported in 
copies per milliliter were divided by 5 to convert to IU/mL.
Statistical Analysis
We used a propensity-score weighting method to adjust for differences between patients who 
had and had not received antiviral therapy. Logistic regression was used to compute the 
probability of receiving treatment (propensity score) based on all previously mentioned 
baseline covariates (study site, patient demographics, ALT elevation, and comorbidity index) 
except baseline serum-based fibrosis markers and HBV DNA viral loads because of 
incompleteness of data, and HIV status because it was time dependent. We then weighted 
each patient’s data based on the inverse of the propensity score.
We examined the risk for HCC using simple Cox regression, followed by multiple Cox 
regression, including the variable of “received antiviral HBV therapy” adjusted by inverse of 
the propensity score. Any variable that showed a significant (P < .05) simple relationship 
with HCC was considered a candidate for the multiple Cox regression model. The final 
model retained variables that showed a significant relationship with HCC (P < .05). All 
analyses were adjusted for study site.
We also conducted several sensitivity analyses. We used a sample matched one-to-one on 
propensity score using a greedy matching algorithm.11 This analysis resulted in 748 treated 
patients (of 820 possible; 91.2%) matched to 748 untreated patients. Two additional 
subgroup analyses were performed: a serum fibrosis marker subgroup analysis that included 
patients for whom baseline laboratory data were available for imputing serum-based fibrosis 
markers (APRI and FIB4, n = 1404), and an HBV DNA viral load subgroup analysis that 
included patients for whom viral load data were available (n = 1986).
In the serum fibrosis marker subgroup analysis, both APRI and FIB4 were included when 
calculating the propensity score and for assessing possible predictors of HCC. Because of a 
high correlation between the two markers (r > .80), each was included one at a time in 
multiple regression modeling if there was a simple relationship with HCC (P < .05).
In the HBV DNA viral load subgroup analysis, baseline ALT was included in the propensity 
score adjustment to balance the treated and untreated groups and also for assessing possible 
predictors of HCC. Viral load was included as a time-dependent covariate for prediction of 
HCC development. Analysis was first tested for treatment by viral load interaction followed 
by assessment of treatment effect at each viral load level, and other subgroup comparisons if 
an interaction was detected at a P = .10 level. A significant interaction indicates that the 
antiviral HBV treatment effect might be influenced by viral load levels, or that viral load 
effects were dependent on the presence or absence of antiviral HBV therapy. The adjusted 
hazard ratio (aHR), 95% confidence interval (CI), and P value were reported.
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Results
We found 4158 chronic HBV infection candidates based on electronic criteria, of which 
2775 were confirmed to have chronic HBV infection based on chart abstraction to date. Of 
the 2775 patients, 99 were coinfected with HCV, and 4 had received a diagnosis of HCC 
more than 60 days before the diagnosis of HBV; these patients were excluded. This left 2671 
patients in the study cohort. The earliest HBV diagnosis was in 1992, and median diagnosis 
year was 2005 (interquartile range, 2002–2007). Median follow-up time was 5.2 years 
(interquartile range, 3–9 years).
Enrollment and demographic information are shown in Table 1. In all, 9% of the patients had 
major comorbidity at baseline (index score of 2 or 3) and 6% tested positive for HIV 
coinfection during follow-up. Over the follow-up period, 67 patients (3%) developed HCC. 
The crude HCC incidence rate was 4.2 cases per 1000 person-years.
Antiviral Hepatitis B Virus Therapy and Risk of Hepatocelluar Carcinoma Development
Of 2671 patients in the study cohort, 820 (31%) received antiviral HBV therapy. Ninety-four 
percent (n = 770) of those treated received nucleos(t)ide analog therapy, alone or before or 
after interferon-based therapy, whereas the remaining 6% received only interferon or 
pegylated interferon-based therapy. Median treatment duration during follow-up was 45 
months (interquartile range, 22–81 months). Twenty patients in the antiviral HBV treatment 
group developed HCC (crude incidence rate, 4.2 per 1000 person-years) versus 47 in the 
group that did not receive antiviral therapy (crude incidence rate, 4.2 per 1000 person-years).
Patients’ characteristics were unbalanced between treated and untreated groups. Patients 
who received antiviral HBV therapy were older, more often male, and less likely to be Asian 
or Pacific Islander than were untreated patients (Table 2). Treated patients also had higher 
comorbidity scores. Among the patients with available laboratory data, a larger proportion of 
the treated patients had abnormal ALT at baseline. After propensity-score adjustment, 
demographic and clinical characteristics were balanced between the comparison groups 
(Table 2).
In simple Cox regression based on the overall cohort, age >40 years, male gender, greater 
comorbidity, and abnormal ALT were significantly associated with an increased risk of HCC 
(Table 3). In contrast, a history of antiviral HBV therapy was significantly associated with a 
reduced incidence of HCC. In multiple Cox regression, older age, male gender, abnormal 
ALT, and comorbidity remained significantly associated with development of HCC (Table 
4). Antiviral therapy was associated with a reduction of HCC (aHR, 0.50; 95% CI, 0.35–
0.72; P <.001), and this reduction persisted in analyses of the matched-pairs cohort (aHR, 
0.48; 95% CI, 0.27–0.86; P = .01).
A total of 1404 patients were included in the serum fibrosis marker subgroup analysis. 
Patients’ demographic characteristics were similar to those among the overall cohort (Table 
1). Patients who received antiviral therapy had higher APRI and FIB4 scores compared with 
those who were not treated (P < .001). After propensity-score adjustment, the demographic 
and clinical characteristics, including APRI and FIB4, were balanced between the treatment 
Gordon et al. Page 5
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 December 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
groups (adjusted P values of 0.21–0.91). The multiple Cox regression results showed that the 
relationship between the use of antiviral HBV therapy and reduced risk of HCC persisted 
(aHR, 0.24; 95% CI, 0.15–0.39; P < .001; Table 4). Higher logFIB4 was also independently 
associated with HCC development (aHR, 1.97; 95% CI, 1.65–2.34; P < .001). In a separate 
multiple model analysis, higher logAPRI was likewise associated with HCC development 
(aHR, 1.43; 95% CI, 1.28–1.61; P < .001).
A total of 1986 patients were included in the HBV DNA viral load subgroup analysis. 
Patients’ demographic characteristics were similar to those among the overall cohort (Table 
1). Patients who received antiviral therapy had higher baseline ALT levels than those in the 
untreated group (P < .001). Among patients with viral levels available at baseline, 70% and 
22% of the treated and untreated groups, respectively, had levels >20,000 IU/mL. After 
propensity-score adjustment, the demographic and clinical characteristics, including baseline 
ALT, were balanced between the treatment groups (adjusted P values of .69–.99). In the 
multiple Cox regression model, a significant interaction between antiviral HBV therapy and 
viral load level was observed (P = .07). Antiviral therapy was consistently associated with a 
lower risk of HCC in all 3 viral load categories, with the largest and statistically significant 
risk reduction observed in the >20,000 IU/mL category (aHR, 0.17; 95% CI, 0.06–0.52; P 
= .002; Table 4). In addition, HCC risk was significantly higher in the > 20,000 IU/mL viral 
load category compared with the <2000 IU/mL category in the untreated group (aHR, 1.92; 
95% CI, 1.16–3.17; P = .011; Table 4) but not in the treated group.
Discussion
In this large American community-based cohort, a history of antiviral therapy for chronic 
HBV infection was associated with a reduction in the risk of HCC over a median of 5 years. 
To our knowledge, this analysis is the only US-based study to show such a benefit, and the 
large size and diversity of the cohort (geographic, clinical, and racial) and long duration of 
follow-up extend the generalizability of similar findings observed in smaller, more 
homogenous populations.
Given that persistent elevations in HBV DNA levels are associated with HCC,12 viral 
suppression of HBV through antiviral therapy intuitively should ameliorate some of the risk 
of carcinogenesis. In the case of HCV infection, successful antiviral therapy that eradicates 
the virus has been associated with a reduced risk of HCC,13 whereas unsuccessful antiviral 
therapy fails to reduce the risk of HCC.14 In a recent comprehensive review, viral 
suppression with antivirals was found to be the most effective way to reduce the incidence of 
HBV-related HCC.1 In our large hepatitis B cohort, multiple Cox regression analysis showed 
that antiviral therapy reduced the risk for HCC (aHR, 0.50; 95% CI, 0.35–0.72; P < .001), 
and the antiviral effect was persistent in sensitivity analyses. Our findings are therefore 
consistent with the predominantly Asian and European analyses included in the review, and 
extend them into a broader, US community-based population.
Age, male gender, degree of comorbidity, and ALT abnormality also were independent 
predictors of HCC in our study, in concordance with previous analyses in persons with 
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chronic HBV infection15 and those with cirrhosis of any etiology.16 In addition, lack of 
reduction in ALT levels12 was also associated with an increased risk for HCC.
The association between antiviral therapy and reduced risk of HCC persisted in the serum 
fibrosis subgroup analysis (aHR, 0.24; 95% CI, 0.15–0.39; P < .001), after adjusting for 
other covariates including logFIB4. Higher logFIB4 was also an independent predictor of 
increased risk of HCC. Notably, however, we found no interaction between logFIB4 and 
antiviral therapy, indicating that antiviral therapy benefits are consistent across the spectrum 
of fibrosis levels. Because previous studies showing antiviral therapy benefit have been 
predominantly in the cirrhotic population,9 we also substituted a dichotomous FIB4 variable 
for logFIB4 in the multiple regression model, using a FIB4 cutoff value of 5.17 for cirrhosis 
that has been validated in the CHeCS HBV population (unpublished data, 2013). The results 
of the model with dichotomous FIB4 were consistent with the results of the model that 
included logFIB4. Antiviral therapy remained associated with a reduced risk of developing 
HCC, and patients with FIB4 levels over 5.17 had significantly higher risk of HCC 
compared with patients with lower FIB4 levels (aHR, 3.95; 95% CI, 2.61–5.97; P < .001). 
We also found no interaction between antiviral therapy and dichotomous FIB4, suggesting 
that patients with and without cirrhosis both benefit from antiviral therapy in reducing the 
risk of HCC. Our study therefore extends previous studies9 by suggesting that antiviral 
therapy effectively reduces the risk of developing HCC across a spectrum of fibrosis levels, 
including in patients without cirrhosis.
The beneficial effect of antiviral therapy persisted in each of the three DNA viral load levels 
in our viral load subgroup analysis, although the largest and statistically significant effect 
was among patients with viral levels >20,000 IU/mL (Table 4). Higher viral loads were 
associated with a higher risk of HCC in the untreated group, whereas in the treated group, 
we did not see a significant difference in risk of HCC among the three viral load categories. 
We also compared risk of HCC in the treated group, after viral load was suppressed to 
<2000 IU/mL, versus the untreated group whose viral loads remained >20,000 IU/mL. We 
found a significantly lower risk in the treated, virally suppressed group (aHR, 0.37; 95% CI, 
0.22–0.65; P < .001).
The major strengths of our study are its size, setting, and diversity. The study represents 
outcomes in real-world scenarios rather than in restrictive clinical trial environments, and is 
not limited to any particular subgroup by e-antigen status, presence of cirrhosis, or other 
viral or disease characteristics. Furthermore, given its setting in 4 large catchment areas, our 
analysis reflects a broad American racial diversity. Finally, the large sample size and 
adjustment for covariates and propensity score enhance the robustness of the findings, as 
does the fact that all available antiviral treatment data were obtained from both internal and 
external records. The observed reduction of HCC risk associated with antiviral therapy 
persisted across the spectrum of liver disease (represented by ALT and FIB4) and HBV viral 
loads.
Our study has several important limitations. First, our ability to assess the significance of 
various clinical and behavioral covariates was limited because study data were collected 
only during the routine process of care. Specifically, we had insufficient data to characterize 
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baseline behavioral characteristics, such as alcohol, tobacco and drug use, e-antigen status, 
genotypes, extent of liver fibrosis determined through histologic assessment, and duration of 
antiviral and other therapies to include as covariates. Thus, we could not assess the possible 
antifibrotic effect of antiviral therapy on HCC risk.17,18 Nevertheless, our inclusion of FIB4 
and APRI as covariates in our serum fibrosis marker subgroup analysis showed that more 
advanced fibrosis in patients with HBV infection was associated with an increased risk for 
HCC, whereas antiviral therapy remained an independent predictor of reduced risk for HCC 
development. Second, because CHeCS participants necessarily represent patients known to 
health systems, they cannot fully represent persons with chronic HBV infection in the 
United States, up to 30% of whom might be unaware of their infection.19 Third, we were not 
able to include body mass index, diabetes, or lipid profiles in our analysis because of the 
high proportion of missing data for these elements. However, we did include the Charlson/
Deyo comorbidity index, which was included in both the propensity score adjustment and as 
a covariate in the Cox regression modeling.
Finally, we used propensity score methods to adjust for differences between the treated and 
untreated groups based on known factors, but this uncontrolled observational study could not 
take into account unknown factors. Although we were not able to incorporate baseline HBV 
DNA levels or e-antigen status in our propensity adjustment, we note that FIB4 scores in the 
serum markers subgroup analysis were balanced between the treated and untreated groups 
after propensity score adjustment.
In conclusion, in this large US-based observational cohort study we found that HBV 
antiviral therapy was associated with a significantly decreased risk of HCC in patients with 
chronic HBV infection. These findings corroborate existing and emerging evidence of the 
beneficial effect of antiviral therapy in reducing risk of HBV-related HCC. Most of these 
studies suggest that the reduced risk of carcinogenesis is the result of suppression of HBV 
through antiviral therapy1; we found that antiviral treatment had a beneficial effect across a 
spectrum of viral load levels. Inclusion of all patients infected with HBV in our community-
based cohort, without restriction to any particular stage of fibrosis or baseline viral level, 
allowed assessment of the effects of antiviral therapy across a range of disease severity. 
There was a wide distribution of FIB4 scores within our serum fibrosis subgroup, and we 
found no interaction between FIB4 levels and antiviral treatment in predicting HCC 
development, indicating that the beneficial effect of treatment is not changed by presumed 
fibrosis level. This is a fairly novel finding, because most studies to date have focused 
primarily on patients with cirrhosis.9 Prospective studies with comprehensive baseline 
fibrosis data collection are needed in additional cohorts to corroborate these findings.
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ALT alanine aminotransferase
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HCC hepatocellular carcinoma
HCV hepatitis C virus
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Table 1
Baseline Demographic and Clinical Characteristics of the Overall HBV Cohort, the Serum Fibrosis Marker 
Subgroup, and the DNA Viral Load Subgroup
Overall (N = 2671)
Serum fibrosis marker subgroup 
(n = 1404)
DNA viral load subgroup (n = 
1986)
Study site
 Kaiser Permanente–Northwest, n (%) 839 (31) 378 (27) 584 (29)
 Kaiser Permanente–Hawaii, n (%) 857 (32) 397 (28) 623 (31)
 Henry Ford Health System, n (%) 823 (31) 535 (38) 673 (34)
 Geisinger Health System, n (%) 152 (6) 94 (7) 106 (5)
Age category, y
 ≤40, n (%) 743 (28) 335 (24) 524 (26)
 >40–50, n (%) 646 (24) 319 (23) 495 (25)
 >50–60, n (%) 669 (25) 371 (26) 508 (26)
 ≥60, n (%) 613 (23) 379 (27) 459 (23)
Male gender, n (%) 1491 (56) 844 (60) 1154 (58)
Race
 Asian, n (%) 1298 (49) 619 (44) 1021 (51)
 White, n (%) 567 (21) 322 (23) 399 (20)
 Black, n (%) 340 (13) 235 (17) 257 (13)
 Pacific Islander/Hawaiian, n (%) 160 (6) 71 (5) 107 (5)
 Native American, n (%) 12 (<1) 7 (<1) 9 (<1)
 Unknown, n (%) 294 (11) 150 (11) 193 (10)
Median annual household income
 <$15,000, n (%) 33 (1) 21 (1) 24 (1)
 ≥$15,000 to <$30,000, n (%) 318 (12) 209 (15) 230 (12)
 ≥$30,000 to <$50,000, n (%) 1061 (40) 566 (40) 775 (39)
 ≥$50,000 to <$75,000, n (%) 857 (32) 402 (29) 635 (32)
 ≥$75,000, n (%) 325 (12) 167 (12) 265 (13)
 Missing, n (%) 77 (3) 39 (3) 57 (3)
Insurance status
 Not insured, n (%) 40 (1) 24 (2) 24 (1)
 Insured, n (%) 2538 (95) 1332 (95) 1901 (96)
 Unknown, n (%) 93 (3) 48 (3) 61 (3)
Charlson/Deyo comorbidity index score
 0, n (%) 1995 (75) 940 (67) 1482 (75)
 1, n (%) 442 (17) 292 (21) 333 (17)
 2 or 3, n (%) 234 (9) 172 (12) 171 (9)
APRI score (n = 1463) (n = 1403) (n = 1108)
 Median (IQR) 0.42 (0.25–0.99) 0.43 (0.26–1.04) 0.46 (0.27–1.04)
FIB4 score (n = 1404) (n = 1404) (n = 1068)
 Median (IQR) 1.25 (0.75–2.24) 1.25 (0.75–2.24) 1.30 (0.78–2.24)
ALT, U/mL
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Overall (N = 2671)
Serum fibrosis marker subgroup 
(n = 1404)
DNA viral load subgroup (n = 
1986)
 Abnormal, n (%)a 746 (28) 573 (41) 595 (30)
 Normal, n (%)a 1470 (55) 831 (59) 1062 (53)
 Unknown, n (%) 455 (17) 0 (0) 329 (17)
aAccording to each site’s reference range.
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Table 2
Characteristics Included in Multiple Cox Regression Modeling in the Overall Cohort, by Receipt of Antiviral 
HBV Therapy, Before and After Propensity Adjustment
Overall cohort (N = 2671)
Received antiviral HBV therapy
Unadjusted P value IPTW-Adjusted P valueNo (n = 1851) Yes (n = 820)
Age category, y
 <40, n (%) 594 (32) 149 (18) <.001 .423
 >40–50, n (%) 431 (23) 215 (26)
 >50–60, n (%) 425 (23) 244 (30)
 ≥60, n (%) 401 (22) 212 (26)
Gender
 Female, n (%) 931 (50) 249 (30) <.001 .772
 Male, n (%) 920 (50) 571 (70)
Race/ethnicity
 Asian/Pacific Islander, n (%) 1062 (57) 396 (48) <.001 .201
 Other, n (%)a 547 (30) 372 (45)
 Unknown, n (%) 242 (13) 52 (6)
Median annual household income
 Missing, n (%) 47 (3) 30 (4) .066 .819
 <$15,000, n (%) 23 (1) 10 (1)
 ≥$15,000 to <$30,000, n (%) 218 (12) 100 (12)
 ≥$30,000 to <$50,000, n (%) 727 (39) 334 (41)
 ≥$50,000 to <$75,000, n (%) 624 (34) 233 (28)
 ≥$75,000, n (%) 212 (11) 113 (14)
Insurance status
 Not insured, n (%) 29 (2) 11 (1) .014 .543
 Insured, n (%) 1745 (94) 793 (97)
 Unknown, n (%) 77 (4) 16 (2)
ALT status
 Normal, n (%)b 1187 (64) 283 (35) <.001 .768
 Abnormal, n (%)b 394 (21) 352 (43)
 Unknown, n (%)b 270 (15) 185 (23)
Charlson/Deyo comorbidity index score
 0 1468 (79) 527 (64) <.001 .494
 1 251 (14) 191 (23)
 2 or 3 132 (7) 102 (12)
IPTW, inverse probability of received treatment weighting.
aWhite, black, or Native American.
bAccording to each site’s reference range.
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Table 3
Simple Associations of Baseline Characteristics With Development of HCC in Cox Proportional Hazard 
Modeling in the Overall HBV Cohort
Hazard ratio (95% CI) P value
Age category, y
 <40 1 (Reference) <.001
 >40–50 5.93 (1.33–26.50)
 >50–60 6.18 (1.40–27.29)
 ≥60 19.33 (4.66–80.22)
Gender
 Female 1 (Reference) <.001
 Male 3.32 (1.81–6.11)
Race
 Asian/Pacific Islander 1 (Reference) .166
 Othera 1.02 (0.56–1.85)
 Unknown 0.15 (0.02–1.08)
Median household income
 <$15,000 1 (Reference) .122
 ≥$15,000 to < $30,000 4.91 (0.65–37.19)
 ≥$30,000 to <$50,000 2.47 (0.33–18.40)
 ≥$50,000 to <$75,000 2.53 (0.33–18.98)
 ≥$75,000 1.91 (0.23–15.59)
HIV coinfection
 HIV 1.06 (0.42–2.66) .901
Charlson/Deyo comorbidity index score
 0 1 (Reference) <.001
 1 2.60 (1.49–4.54)
 2 or 3 3.54 (1.83–6.84)
Insurance status
 Not insured 1 (Reference) .130
 Insured 0.85 (0.12–6.25)
 Unknown 2.48 (0.26–23.63)
ALT
 ALT normalb 1 (Reference) <.001
 ALT abnormalb 4.44 (2.46–8.01)
Antiviral HBV treatmentc 0.50 (0.35–0.72) <.001
aWhite, black, or Native American.
bAccording to each site’s reference range.
cAfter adjustment for inverse probability of received treatment weighting.
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 December 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gordon et al. Page 16
Ta
bl
e 
4
Fi
na
l M
ul
tip
le
 C
ox
 R
eg
re
ss
io
n 
M
od
el
s f
or
 P
re
di
ct
io
n 
of
 H
CC
 in
 th
e 
O
ve
ra
ll 
H
BV
 C
oh
or
t, 
th
e 
Se
ru
m
 F
ib
ro
sis
 M
ar
ke
r 
Su
bg
ro
up
, a
nd
 th
e 
D
NA
 V
ira
l L
oa
d 
Su
bg
ro
up
O
ve
ra
ll 
co
ho
rt
Se
ru
m
 fi
br
o
sis
 m
ar
ke
r 
su
bg
ro
u
p
D
N
A
 v
ir
al
 lo
ad
 su
bg
ro
u
p
H
az
ar
d 
ra
tio
a
 
(95
%
 C
I)
P 
v
a
lu
e
H
az
ar
d 
ra
tio
a
 
(95
%
 C
I)
P 
v
a
lu
e
H
az
ar
d 
ra
tio
a
 
(95
%
 C
I)
P 
v
a
lu
e
A
ge
, y
<
.0
01
.
05
5
<
.0
01
 
>
40
–5
0 
vs
 <
40
5.
51
 (1
.74
–1
7.4
2)
.
00
4
7.
67
 (1
.33
–4
4.1
0)
.
02
3
3.
53
 (1
.17
–1
0.4
9)
.
02
5
 
>
50
–6
0 
vs
 <
40
5.
55
 (1
.78
–1
7.2
8)
.
00
3
7.
96
 (1
.40
–4
5.2
0)
.
01
9
4.
37
 (1
.51
–1
2.6
6)
.
00
7
 
≥6
0 
vs
 <
40
13
.7
7 
(4.
54
–4
1.7
6)
<
.0
01
9.
94
 (1
.78
–5
5.6
9)
.
00
9
8.
78
 (3
.08
–2
5.0
3)
<
.0
01
M
al
e 
vs
 fe
m
al
e 
ge
nd
er
2.
29
 (1
.46
–3
.59
)
<
.0
01
4.
70
 (2
.34
–9
.42
)
<
.0
01
1.
60
 (1
.00
–2
.56
)
.
05
1
Ch
ar
lso
n/
D
ey
o 
co
m
or
bi
di
ty
 in
de
x
<
.0
01
<
.0
01
<
.0
01
 
Sc
or
e 
of
 1
 v
s 0
2.
15
 (1
.44
–3
.21
)
<
.0
01
2.
11
 (1
.30
–3
.43
)
.
00
3
2.
16
 (1
.36
–3
.43
)
.
00
1
 
2 
or
 3
 v
s 0
2.
55
 (1
.62
–4
.02
)
<
.0
01
2.
91
 (1
.78
–4
.78
)
<
.0
01
2.
58
 (1
.54
–4
.31
)
<
.0
01
A
LT
 
A
bn
or
m
al
 v
s n
or
m
al
4.
41
 (2
.81
–6
.90
)
<
.0
01
—
—
4.
88
 (2
.90
–8
.23
)
<
.0
01
lo
gF
IB
4b
—
—
1.
97
 (1
.65
–2
.34
)
<
.0
01
—
—
lo
gA
PR
I
—
—
1.
43
 (1
.28
–1
.61
)
<
.0
01
—
—
A
nt
iv
ira
l H
BV
 th
er
ap
y
 
R
ec
ei
v
ed
 v
s n
ot
 re
ce
iv
ed
0.
50
 (0
.35
–0
.72
)
<
.0
01
0.
24
 (0
.15
–0
.39
)
<
.0
01
—
—
A
nt
iv
ira
l H
BV
 th
er
ap
y 
* 
D
N
A
 le
v
el
 (i
nte
rac
tio
n)
.
07
2
 
Tr
ea
tm
en
t e
ffe
ct
:
 
 
Tr
ea
te
d 
vs
 u
nt
re
at
ed
: >
20
,0
00
 IU
/m
L
—
—
—
—
0.
17
 (0
.06
–0
.52
)
.
00
2
 
 
Tr
ea
te
d 
vs
 u
nt
re
at
ed
: 2
00
0–
20
,0
00
 IU
/m
L
—
—
—
—
0.
45
 (0
.14
–1
.47
)
.
18
5
 
 
Tr
ea
te
d 
vs
 u
nt
re
at
ed
: <
20
00
 IU
/m
L
—
—
—
—
0.
72
 (0
.43
–1
.20
)
.
20
6
 
Vi
ra
l l
oa
d 
ef
fe
ct
: t
re
at
ed
 g
ro
up
 
 
>
20
,0
00
 v
s <
20
00
 IU
/m
L
—
—
—
—
0.
46
 (0
.15
–1
.40
)
.
17
0
 
 
20
00
–2
0,
00
0 
vs
 <
20
00
 IU
/m
L
—
—
—
—
1.
10
 (0
.35
–3
.39
)
.
87
6
 
Vi
ra
l l
oa
d 
ef
fe
ct
: u
nt
re
at
ed
 g
ro
up
 
 
>
20
,0
00
 v
s <
20
00
 IU
/m
L
1.
92
 (1
.16
–3
.17
)
.
01
1
 
 
20
00
–2
0,
00
0 
vs
 <
20
00
 IU
/m
L
1.
75
 (0
.94
–3
.25
)
.
07
7
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 December 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gordon et al. Page 17
a A
fte
r a
dju
stm
en
t fo
r p
rop
en
sit
y s
co
re 
an
d s
tud
y s
ite
.
b T
he
 e
sti
m
at
ed
 A
PR
I e
ffe
ct
 w
as
 d
er
iv
ed
 fr
om
 th
e 
se
co
nd
 m
ul
tip
le
 C
ox
 re
gr
es
sio
n 
w
he
n 
FI
B4
 w
as
 a
bs
en
t. 
Th
e 
ot
he
r c
ov
ar
ia
te
s, 
in
cl
ud
in
g 
an
tiv
ira
l H
BV
 th
er
ap
y,
 
ha
d 
sim
ila
r e
ffe
ct
s a
cr
os
s t
he
 tw
o
 
m
u
lti
v
ar
ia
bl
e 
m
od
el
s.
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2017 December 07.
